Danaher Corporation Earnings Recaps
Q1 2026
Apr 21, 2026
Danaher delivered a solid start to 2026 with modest core revenue growth driven by strength in bioprocessing and Life Sciences, amid a lighter respiratory season; adjusted EPS rose nearly 10%, supported by operational efficiencies and strategic M&A activity.
Key takeaways
- Core revenue increased 0.5% YoY, with a 3% growth in non-respiratory segments offsetting a 2.5% decline in respiratory revenue.
- Adjusted EPS grew 9.5% to $2.06, aided by cost savings and robust free cash flow generation of $1.1 billion.
- Strategic M&A progress includes the pending Masimo acquisition, expected to be accretive within the first year and deliver high single-digit Returns by Year 5.
- Growth in China accelerated, with Life Sciences and Biotechnology outperforming expectations despite continued headwinds in Diagnostics.
- Operational focus remains on leveraging DBS to enhance innovation, margins, and customer value, with new product launches reinforcing competitive positioning.